Smart Coacervate Droplets Boost miRNA Delivery Tenfold for Lung Inflammation
Researchers engineered antioxidant peptide-based coacervate droplets that deliver therapeutic miRNA 10× more efficiently, easing acute lung injury in mice.
Summary
Scientists at Zhejiang University developed a novel drug delivery system using coacervate droplets — tiny fluid condensates formed by liquid-liquid phase separation of sodium hexametaphosphate and the antioxidant peptide SS-31. These droplets were loaded with microRNA-223, a molecule that shifts immune cells toward an anti-inflammatory state. An additional red blood cell membrane coating protected the cargo from enzymatic degradation in the bloodstream. In mouse models of acute lung injury, both direct lung delivery and intravenous injection of the coated system significantly reduced inflammation, reprogrammed macrophages to a healing phenotype, and lowered oxidative stress. Cytoplasmic delivery efficiency was 10-fold higher than unpackaged miRNA, suggesting coacervate-based carriers could transform RNA therapeutic strategies for inflammatory and immune diseases.
Detailed Summary
RNA-based medicines hold enormous promise for treating inflammatory and immune diseases, but a persistent bottleneck has been getting fragile RNA molecules safely and efficiently into target cells. Enzymes in the blood rapidly degrade naked RNA, and cellular uptake into the cytoplasm — where RNA exerts its effects — remains poor. New delivery solutions are urgently needed.
Researchers developed coacervate artificial cells (Coac@miR) by mixing sodium hexametaphosphate (SHMP) with the mitochondria-targeting antioxidant peptide SS-31 under conditions that trigger liquid-liquid phase separation. This spontaneously produces dense, fluid micro-droplets capable of loading microRNA-223, a well-characterized regulator of inflammatory signaling. To protect the cargo during systemic circulation, the team wrapped these droplets in erythrocyte (red blood cell) membrane shells, creating EMCoac@miR.
Key results were striking: cytoplasmic delivery of miRNA-223 was 10-fold more efficient with the coacervate carrier compared to free miRNA. In an acute lung injury (ALI) mouse model, both intratracheal injection of uncoated Coac@miR and intravenous injection of EMCoac@miR reduced lung inflammation meaningfully. The mechanism involved reprogramming macrophages from a pro-inflammatory (M1) to an anti-inflammatory, tissue-repairing (M2) phenotype, suppressing inflammatory cytokines, and reducing reactive oxygen species (ROS) stress — a triple therapeutic action.
The dual-route efficacy and built-in antioxidant functionality of SS-31 make this platform particularly attractive for diseases where oxidative stress and inflammation converge, including many age-related conditions. The erythrocyte membrane coating also offers a stealth strategy to evade immune clearance during circulation.
Caveats include reliance on mouse models, which may not fully replicate human lung immunology. The long-term safety, biodistribution, and scalability of coacervate production remain to be established. The study also focuses on a single miRNA target, limiting generalizability across disease contexts.
Key Findings
- Coacervate droplets delivered miRNA-223 into the cytoplasm 10× more efficiently than unpackaged miRNA.
- Erythrocyte membrane coating shielded miRNA from ribonuclease degradation during blood circulation.
- Both intratracheal and intravenous routes alleviated acute lung injury in mouse models.
- Treatment reprogrammed macrophages to anti-inflammatory M2 phenotype and suppressed pro-inflammatory cytokines.
- Antioxidant peptide SS-31 component simultaneously reduced reactive oxygen species stress in injured lungs.
Methodology
The study used in vitro characterization of coacervate droplets formed by SHMP and SS-31 peptide, followed by miRNA-223 loading and erythrocyte membrane coating. Efficacy was tested in an acute lung injury mouse model via both intratracheal and intravenous administration routes, with endpoints including cytoplasmic delivery efficiency, macrophage phenotyping, cytokine profiling, and ROS measurement.
Study Limitations
Findings are based solely on mouse models, which may not translate directly to human lung biology or immune responses. Long-term safety, immunogenicity of the erythrocyte membrane coating, and manufacturing scalability have not been assessed. The study examines only miRNA-223 and acute lung injury, so broader applicability requires further validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.